{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:33:35Z","timestamp":1793316815461,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03576-3","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:21:36Z","timestamp":1792704096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PLGA-Phospholipid Hybrid Oleogel In Situ Forming Implant for Sustained 30-Day Co-Delivery of Donepezil and Memantine"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-5196","authenticated-orcid":false,"given":"Baljinder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-884X","authenticated-orcid":false,"given":"Weranga","family":"Rajapaksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-707X","authenticated-orcid":false,"given":"Haripriya","family":"Koppisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-1236","authenticated-orcid":false,"given":"Deepa","family":"Nakmode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-5895","authenticated-orcid":false,"given":"Yunmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-2629","authenticated-orcid":false,"given":"Sanjay","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3576_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2020.05.044","volume":"325","author":"B Wilson","year":"2020","unstructured":"Wilson B, Geetha KM. Neurotherapeutic applications of nanomedicine for treating Alzheimer\u2019s disease. J Control Release. 2020;325:25\u201337.","journal-title":"J Control Release"},{"key":"3576_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, et al. Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024;367:402\u201324.","journal-title":"J Control Release"},{"issue":"9","key":"3576_CR3","doi-asserted-by":"publisher","first-page":"e1534","DOI":"10.1016\/S2214-109X(24)00264-X","volume":"12","author":"S Chen","year":"2024","unstructured":"Chen S, et al. The global macroeconomic burden of Alzheimer\u2019s disease and other dementias: estimates and projections for 152 countries or territories. Lancet Glob Health. 2024;12(9):e1534\u201343.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"3576_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/jnr.10426","volume":"70","author":"T Kihara","year":"2002","unstructured":"Kihara T, et al. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res. 2002;70(3):274\u201382.","journal-title":"J Neurosci Res"},{"issue":"4537","key":"3576_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"PJ Whitehouse","year":"1982","unstructured":"Whitehouse PJ, et al. Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237\u20139.","journal-title":"Science"},{"key":"3576_CR6","doi-asserted-by":"crossref","unstructured":"Fayed N, et al. Brain glutamate levels are decreased in Alzheimer\u2019s disease: a magnetic resonance spectroscopy study. Am J Alzheimer's Dis Other Dementias\u00ae. 2011;26(6):450\u2013456.","DOI":"10.1177\/1533317511421780"},{"issue":"9","key":"3576_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4140\/TCP.n.2017.511","volume":"32","author":"BE Glynn-Servedio","year":"2017","unstructured":"Glynn-Servedio BE, Ranola TS. AChE inhibitors and NMDA receptor antagonists in advanced Alzheimer\u2019s disease. Consult Pharm. 2017;32(9):511\u20138.","journal-title":"Consult Pharm"},{"issue":"1","key":"3576_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s43856-024-00527-6","volume":"4","author":"E Yaghmaei","year":"2024","unstructured":"Yaghmaei E, et al. Combined use of donepezil and memantine increases the probability of five-year survival of Alzheimer\u2019s disease patients. Commun Med. 2024;4(1):99.","journal-title":"Commun Med"},{"issue":"11","key":"3576_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1831","volume":"10","author":"J Guo","year":"2020","unstructured":"Guo J, et al. Memantine, donepezil, or combination therapy\u2014what is the best therapy for Alzheimer\u2019s disease? A network meta-analysis. Brain Behav. 2020;10(11):e01831.","journal-title":"Brain Behav"},{"key":"3576_CR10","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/DDDT.S86463","volume":"10","author":"WJ Deardorff","year":"2016","unstructured":"Deardorff WJ, Grossberg G. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease. Drug Des Devel Ther. 2016;10:3267\u201379.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"3576_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1527-3458.2001.tb00204.x","volume":"7","author":"M Shigeta","year":"2006","unstructured":"Shigeta M, Homma A. Donepezil for Alzheimer\u2019s disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev. 2006;7(4):353\u201368.","journal-title":"CNS Drug Rev"},{"issue":"1","key":"3576_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","volume":"14","author":"B-H Kim","year":"2025","unstructured":"Kim B-H, et al. Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener. 2025;14(1):6.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"3576_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1370\/afm.3050","volume":"22","author":"MH Ebell","year":"2024","unstructured":"Ebell MH, et al. Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis. Ann Fam Med. 2024;22(1):50\u201362.","journal-title":"Ann Fam Med"},{"key":"3576_CR14","unstructured":"Drugbank. Memantine. [cited 2025 20 May]."},{"key":"3576_CR15","unstructured":"Drugbank. Donepzil. [cited 2025 20 May]; Available from: https:\/\/go.drugbank.com\/drugs\/DB00843."},{"issue":"3","key":"3576_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/1574884710666150812141525","volume":"10","author":"R Elliott","year":"2015","unstructured":"Elliott R, et al. Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review. Curr Clin Pharmacol. 2015;10(3):213\u201321.","journal-title":"Curr Clin Pharmacol"},{"key":"3576_CR17","first-page":"1","volume-title":"Long acting injections and implants","author":"DJ Burgess","year":"2011","unstructured":"Burgess DJ, Wright JC. An introduction to long acting injections and implants. In: Long acting injections and implants. Springer; 2011. p. 1\u20139."},{"issue":"5","key":"3576_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41578-021-00405-w","volume":"7","author":"W Li","year":"2022","unstructured":"Li W, et al. Clinical translation of long-acting drug delivery formulations. Nat Rev Mater. 2022;7(5):406\u201320.","journal-title":"Nat Rev Mater"},{"issue":"10","key":"3576_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/17425247.2022.2106213","volume":"19","author":"C Bassand","year":"2022","unstructured":"Bassand C, et al. Smart design of patient-centric long-acting products: from preclinical to marketed pipeline trends and opportunities. Expert Opin Drug Deliv. 2022;19(10):1265\u201383.","journal-title":"Expert Opin Drug Deliv"},{"key":"3576_CR20","doi-asserted-by":"crossref","unstructured":"Nakmode DD, et al. Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies. Drug Deliv Transl Res. 2024;1\u201325.","DOI":"10.1007\/s13346-024-01781-w"},{"issue":"1","key":"3576_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","volume":"172","author":"M Parent","year":"2013","unstructured":"Parent M, et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J Control Release. 2013;172(1):292\u2013304.","journal-title":"J Control Release"},{"key":"3576_CR22","unstructured":"Chieh-Cheng H, et al. An implantable depot that can generate oxygen in situ for overcoming hypoxia-induced resistance to anticancer drugs in chemotherapy. 2016."},{"issue":"1","key":"3576_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s13346-025-01871-3","volume":"16","author":"SA Howard","year":"2026","unstructured":"Howard SA, et al. First-in-line subcutaneous injectable for reversible, non-hormonal male contraception. Drug Deliv Transl Res. 2026;16(1):347\u201366.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"3576_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12141-5","volume":"10","author":"SR Benhabbour","year":"2019","unstructured":"Benhabbour SR, et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat Commun. 2019;10(1):4324.","journal-title":"Nat Commun"},{"issue":"2","key":"3576_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejpb.2004.03.003","volume":"58","author":"C Packhaeuser","year":"2004","unstructured":"Packhaeuser C, et al. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58(2):445\u201355.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"3576_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","volume":"18","author":"P Agarwal","year":"2013","unstructured":"Agarwal P, Rupenthal ID. Injectable implants for the sustained release of protein and peptide drugs. Drug Discov Today. 2013;18(7):337\u201349.","journal-title":"Drug Discov Today"},{"key":"3576_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105460","volume":"93","author":"Z Yang","year":"2024","unstructured":"Yang Z, et al. Design of an injectable sustained release in-situ forming depot of meloxicam for pain relief. J Drug Deliv Sci Technol. 2024;93:105460.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"3576_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jbm.a.32724","volume":"94","author":"RB Patel","year":"2010","unstructured":"Patel RB, et al. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J Biomed Mater Res A. 2010;94(2):476\u201384.","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"3576_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/2230-973X.108961","volume":"3","author":"K Garala","year":"2013","unstructured":"Garala K, et al. Formulation and evaluation of periodontal in situ gel. Int J Pharm Investig. 2013;3(1):29.","journal-title":"Int J Pharm Investig"},{"key":"3576_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1208\/s12249-011-9625-y","volume":"12","author":"F Cilurzo","year":"2011","unstructured":"Cilurzo F, et al. Injectability evaluation: an open issue. AAPS PharmSciTech. 2011;12:604\u20139.","journal-title":"AAPS PharmSciTech"},{"issue":"4\u20135","key":"3576_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ejps.2008.12.003","volume":"36","author":"W Rungseevijitprapa","year":"2009","unstructured":"Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci. 2009;36(4\u20135):524\u201331.","journal-title":"Eur J Pharm Sci"},{"key":"3576_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jddst.2017.11.001","volume":"43","author":"RA Karthick","year":"2018","unstructured":"Karthick RA, Devi DR, Hari BV. Investigation of sustained release mucoadhesive in-situ gel system of Secnidazole for the persistent treatment of vaginal infections. J Drug Deliv Sci Technol. 2018;43:362\u20138.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3576_CR33","doi-asserted-by":"crossref","unstructured":"Choi G-W, et al. Long-acting injectable donepezil microspheres: Formulation development and evaluation. J Control Release. 2021\/12\/10. 340.","DOI":"10.1016\/j.jconrel.2021.10.022"},{"key":"3576_CR34","doi-asserted-by":"crossref","unstructured":"Singh B, et al. Simultaneous quantification of donepezil and memantine by HPLC\u2013refractive index detection for novel drug delivery systems. BMC Chem. 2026.","DOI":"10.1186\/s13065-026-01835-9"},{"issue":"1","key":"3576_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13065-026-01835-9","volume":"20","author":"B Singh","year":"2026","unstructured":"Singh B, et al. Simultaneous quantification of donepezil and memantine by HPLC\u2013refractive index detection for novel drug delivery systems. BMC Chem. 2026;20(1):161.","journal-title":"BMC Chem"},{"issue":"6","key":"3576_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061188","volume":"14","author":"JB Joiner","year":"2022","unstructured":"Joiner JB, Prasher A, Young IC, Kim J, Shrivastava R, Maturavongsadit P, et al. Effects of drug physicochemical properties on in-situ forming implant polymer degradation and drug release kinetics. Pharmaceutics. 2022;14(6):1188.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3576_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ijpharm.2012.02.015","volume":"427","author":"L Wang","year":"2012","unstructured":"Wang L, et al. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int J Pharm. 2012;427(2):284\u201392.","journal-title":"Int J Pharm"},{"key":"3576_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jconrel.2023.10.006","volume":"363","author":"IC Young","year":"2023","unstructured":"Young IC, et al. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy. J Control Release. 2023;363:606\u201320.","journal-title":"J Control Release"},{"issue":"10","key":"3576_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.31083\/ph.2013.3008","volume":"68","author":"Y Zhong","year":"2013","unstructured":"Zhong Y, et al. Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics. Pharmazie. 2013;68(10):811\u20135.","journal-title":"Pharmazie"},{"issue":"3","key":"3576_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejpb.2004.10.005","volume":"59","author":"H Grohganz","year":"2005","unstructured":"Grohganz H, Tho I, Brandl M. Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix. Eur J Pharm Biopharm. 2005;59(3):439\u201348.","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"3576_CR41","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s13346-023-01349-0","volume":"13","author":"R Tao","year":"2023","unstructured":"Tao R, et al. Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole. Drug Deliv Transl Res. 2023;13(11):2819\u201333.","journal-title":"Drug Deliv Transl Res"},{"issue":"11","key":"3576_CR42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/j.2042-7158.2010.01024.x","volume":"62","author":"H Bunjes","year":"2010","unstructured":"Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J Pharm Pharmacol. 2010;62(11):1637\u201345.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"3576_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jsps.2023.02.002","volume":"31","author":"E Gomaa","year":"2023","unstructured":"Gomaa E, et al. Development of depot PLGA-based in-situ implant of Linagliptin: sustained release and glycemic control. Saudi Pharm J. 2023;31(4):499\u2013509.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"3576_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/03639045.2012.660952","volume":"39","author":"J Camargo","year":"2013","unstructured":"Camargo J, et al. Injectable PLA-based in situ forming implants for controlled release of ivermectin a BCS class II drug: solvent selection based on physico-chemical characterization. Drug Dev Ind Pharm. 2013;39(1):146\u201355.","journal-title":"Drug Dev Ind Pharm"},{"key":"3576_CR45","unstructured":"Food U, Administraion D. CFR-code of federal regulations title 21. 2017. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32."},{"issue":"1-2","key":"3576_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijpharm.2010.05.042","volume":"395","author":"J-J Xuan","year":"2010","unstructured":"Xuan J-J, et al. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. Int J Pharm. 2010;395(1\u20132):317\u201323.","journal-title":"Int J Pharm"},{"issue":"1","key":"3576_CR47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/app.35584","volume":"125","author":"B Wang","year":"2012","unstructured":"Wang B, et al. Rheological properties of PLGA-PEG-PLGA copolymers for ophthalmic injection. J Appl Polym Sci. 2012;125(1):370\u20135.","journal-title":"J Appl Polym Sci"},{"issue":"3","key":"3576_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/apnr.2002.34142","volume":"15","author":"LH Nicoll","year":"2002","unstructured":"Nicoll LH, Hesby A. Intramuscular injection: an integrative research review and guideline for evidence-based practice. Appl Nurs Res. 2002;15(3):149\u201362.","journal-title":"Appl Nurs Res"},{"issue":"2","key":"3576_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/05704920701829043","volume":"43","author":"Z Movasaghi","year":"2008","unstructured":"Movasaghi Z, Rehman S, ur Rehman DI. Fourier transform infrared (FTIR) spectroscopy of biological tissues. Appl Spectrosc Rev. 2008;43(2):134\u201379.","journal-title":"Appl Spectrosc Rev"},{"issue":"11","key":"3576_CR50","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/pharmaceutics16111364","volume":"16","author":"RA Husseini","year":"2024","unstructured":"Husseini RA, et al. Fabrication and optimization of a silodosin in situ-forming PLGA implants for the treatment of benign prostatic hyperplasia: in vitro and in vivo study. Pharmaceutics. 2024;16(11):1364.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3576_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/pharmaceutics16010115","volume":"16","author":"EO Bakhrushina","year":"2024","unstructured":"Bakhrushina EO, et al. Burst release from in situ forming PLGA-based implants: 12 effectors and ways of correction. Pharmaceutics. 2024;16(1):115.","journal-title":"Pharmaceutics"},{"issue":"10","key":"3576_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/pharmaceutics11100520","volume":"11","author":"X Zhang","year":"2019","unstructured":"Zhang X, et al. Effect of polymer permeability and solvent removal rate on in situ forming implants: drug burst release and microstructure. Pharmaceutics. 2019;11(10):520.","journal-title":"Pharmaceutics"},{"issue":"10","key":"3576_CR53","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1002\/jps.24558","volume":"104","author":"L Solorio","year":"2015","unstructured":"Solorio L, et al. The effect of additives on the behavior of phase sensitive in situ forming implants. J Pharm Sci. 2015;104(10):3471\u201380.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3576_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1208\/s12248-022-00695-0","volume":"24","author":"JC Shah","year":"2022","unstructured":"Shah JC, Hong J. Model for long acting injectables (depot formulation) based on pharmacokinetics and physical chemical properties. AAPS J. 2022;24(3):44.","journal-title":"AAPS J"},{"issue":"1","key":"3576_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgaf080","volume":"78","author":"A Otte","year":"2026","unstructured":"Otte A, Park K, Li T. Challenges and innovations in long-acting injectable formulations: can formulation design space be rationalized? J Pharm Pharmacol. 2026;78(1):rgaf080.","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"3576_CR56","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/pharmaceutics16070875","volume":"16","author":"J Dong","year":"2024","unstructured":"Dong J, et al. The advances in phospholipids-based phase separation gels for the sustained release of peptides, proteins, and chemotherapeutics. Pharmaceutics. 2024;16(7):875.","journal-title":"Pharmaceutics"},{"key":"3576_CR57","unstructured":"Dash S. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010."},{"issue":"2","key":"3576_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123\u201333.","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"3576_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijpharm.2005.10.044","volume":"309","author":"V Papadopoulou","year":"2006","unstructured":"Papadopoulou V, et al. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 2006;309(1\u20132):44\u201350.","journal-title":"Int J Pharm"},{"issue":"2","key":"3576_CR60","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ejpb.2008.05.010","volume":"70","author":"M Schwab","year":"2008","unstructured":"Schwab M, et al. Correlation of in vivo and in vitro release data for rh-INF\u03b1 lipid implants. Eur J Pharm Biopharm. 2008;70(2):690\u20134.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"3576_CR61","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s11095-016-1873-9","volume":"33","author":"M Hu","year":"2016","unstructured":"Hu M, et al. Long-acting phospholipid gel of exenatide for long-term therapy of type II diabetes: Hu et al. Pharm Res. 2016;33(6):1318\u201326.","journal-title":"Pharm Res"},{"key":"3576_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2018.03.003","volume":"276","author":"Q Bao","year":"2018","unstructured":"Bao Q, et al. In vitro and ex vivo correlation of drug release from ophthalmic ointments. J Control Release. 2018;276:93\u2013101.","journal-title":"J Control Release"},{"issue":"2","key":"3576_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/00914037.2015.1055633","volume":"65","author":"M Rahimi","year":"2016","unstructured":"Rahimi M, Mobedi H, Behnamghader A. In situ forming poly (lactic acid-co-glycolic acid) implants containing leuprolide acetate\/\u03b2-cyclodextrin complexes: preparation, characterization, and in vitro drug release. Int J Polym Mater Polym Biomater. 2016;65(2):75\u201384.","journal-title":"Int J Polym Mater Polym Biomater"},{"key":"3576_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119439","volume":"586","author":"R Kaur","year":"2020","unstructured":"Kaur R, et al. Development of mirtazapine loaded solid lipid nanoparticles for topical delivery: optimization, characterization and cytotoxicity evaluation. Int J Pharm. 2020;586:119439.","journal-title":"Int J Pharm"},{"issue":"7","key":"3576_CR65","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s11095-022-03391-y","volume":"40","author":"A Bauer","year":"2023","unstructured":"Bauer A, et al. Current state and opportunities with long-acting injectables: industry perspectives from the innovation and quality consortium \u201cLong-Acting Injectables\u201d working group: Andrea et al. Pharm Res. 2023;40(7):1601\u201331.","journal-title":"Pharm Res"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03576-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:01:14Z","timestamp":1793314874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03576-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":65,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3576"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03576-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to correct \"Donepezil\" in the article title. It was incorrectly published as \"Dosnepezil\".","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable\n                      .","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used an AI tool like ChatGPT (OpenAI) for copy editing to improve readability, grammar, spelling, and punctuation. The authors reviewed and edited the output and took full responsibility for the final content of the manuscript.","order":4,"name":"Ethics","label":"Use of Artificial Intelligence (AI)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"332"}}